+1 Recommend
0 collections
      • Record: found
      • Abstract: not found
      • Article: not found

      Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Adiponectin is a novel, adipose-specific protein abundantly present in the circulation, and it has antiatherogenic properties. We analyzed the plasma adiponectin concentrations in age- and body mass index (BMI)-matched nondiabetic and type 2 diabetic subjects with and without coronary artery disease (CAD). Plasma levels of adiponectin in the diabetic subjects without CAD were lower than those in nondiabetic subjects (6.6+/-0.4 versus 7.9+/-0.5 microg/mL in men, 7.6+/-0.7 versus 11.7+/-1.0 microg/mL in women; P<0.001). The plasma adiponectin concentrations of diabetic patients with CAD were lower than those of diabetic patients without CAD (4.0+/-0.4 versus 6.6+/-0.4 microg/mL, P<0.001 in men; 6.3+/-0.8 versus 7.6+/-0. 7 microg/mL in women). In contrast, plasma levels of leptin did not differ between diabetic patients with and without CAD. The presence of microangiopathy did not affect the plasma adiponectin levels in diabetic patients. Significant, univariate, inverse correlations were observed between adiponectin levels and fasting plasma insulin (r=-0.18, P<0.01) and glucose (r=-0.26, P<0.001) levels. In multivariate analysis, plasma insulin did not independently affect the plasma adiponectin levels. BMI, serum triglyceride concentration, and the presence of diabetes or CAD remained significantly related to plasma adiponectin concentrations. Weight reduction significantly elevated plasma adiponectin levels in the diabetic subjects as well as the nondiabetic subjects. These results suggest that the decreased plasma adiponectin concentrations in diabetes may be an indicator of macroangiopathy.

          Related collections

          Most cited references 14

          • Record: found
          • Abstract: not found
          • Article: not found

          cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).

            • Record: found
            • Abstract: not found
            • Article: not found

            The pathogenesis of coronary artery disease and the acute coronary syndromes (1).

              • Record: found
              • Abstract: found
              • Article: not found

              Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity.

              The presence of obesity increases the risk of thrombotic vascular diseases. The role of fat accumulation and its effect on plasminogen activator inhibitor-1 (PAI-1) levels was investigated in humans and animals. Plasma PAI-1 levels were closely correlated with visceral fat area but not with subcutaneous fat area in human subjects. PAI-1 mRNA was detected in both types of fat tissue in obese rats but increased only in visceral fat during the development of obesity. These data suggest that an enhanced expression of the PAI-1 gene in visceral fat may increase plasma levels and may have a role in the development of vascular disease in visceral obesity.

                Author and article information

                Arteriosclerosis, Thrombosis, and Vascular Biology
                Arterioscler Thromb Vasc Biol
                Ovid Technologies (Wolters Kluwer Health)
                June 2000
                June 2000
                : 20
                : 6
                : 1595-1599
                [1 ]From the Department of Internal Medicine and Molecular Science (K. Hotta, T.F., Y.A., M.T., M. Matsuda, Y. Okamoto, H.I., H.K., N.O., K.M., M.N., S.K., N.S., T. Nakamura, S.Y., T.H., Y.M.), Graduate School of Medicine, Osaka University, Osaka, Japan; the Toyonaka City Hospital (T. Nakajima), Osaka, Japan; the Health Administration Department (K. Hasegawa), ITOCHU Corporation, Osaka, Japan; and the Cellular Technology Institute (M. Muraguchi, Y. Ohmoto), Otsuka Pharmaceutical Co, Ltd., Tokushima, Japan.
                © 2000

                Molecular medicine, Neurosciences


                Comment on this article